Nymox Pharmaceutical Corp (NASDAQ:NYMX)

1.39
Delayed Data
As of Apr 24
 -0.048 / -3.34%
Today’s Change
0.33
Today|||52-Week Range
5.75
+247.50%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Medical Specialties
MARKET CAP
$51.1M

Company Description

Nymox Pharmaceutical Corp. is a biopharmaceutical company, which specializes in the research and development of products for the aging population. Currently, it markets NicAlertTM and TobacAlertTM, tests that use urine or saliva to detect use of tobacco products. The company develops NX-1207, a novel treatment for benign prostatic hyperplasia, which is in Phase 3 clinical trials. It also has pipeline drug candidates aimed at the causes of Alzheimer's disease and new treatments of bacterial infections in humans. Nymox Pharmaceutical was founded by Paul Averback on May 30, 1995 and is headquartered in St.-Laurent, Canada.

Contact Information

Nymox Pharmaceutical Corp.
9900, boulevard Cavendish
Saint-Laurent Quebec H4M 2V2
P:(800) 936-9669
Investor Relations:

Employees

Shareholders

Other institutional4.13%
Mutual fund holders1.65%
Individual stakeholders--

Top Executives

Paul AverbackChairman, President & Chief Executive Officer
André MonetteChief Financial Officer
Jack GemmellChief Information Officer
Brian DoyleDirector-Business Development

To view my watchlist

Not a member yet?

Sign up now for a free account